(lp0
S'The Medicines Company and Alnylam Pharmaceuticals Report Positive Final ... Yahoo Finance - 22 hours ago The Medicines Company  and Alnylam Pharmaceuticals, Inc.  today announced positive final results from the ORION-1 Phase II study of inclisiran, an investigational, first-in-class PCSK9 synthesis inhibitor being developed for the treatment ...Alnylam touts latest trial data as suggesting its drugs are safe - Boston Business Journal'
p1
aS"Here's Why Alnylam Pharmaceuticals, Inc. Stock Bounced Up 10.1% Today Motley Fool - Feb 27, 2017 Shares of Alnylam Pharmaceuticals, Inc.  a clinical-stage biotech, notched a 10.1% gain to end Monday's session.Alnylam Pharmaceuticals Inc. - Receive News &amp; Ratings Daily - Chaffey BreezeWhy Analysts put forward these two stocks: Alnylam Pharmaceuticals, Inc. (ALNY ... - The USA Commerce"
p2
aS"Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc. Motley Fool - Feb 20, 2017 Late last year, Alnylam Pharmaceuticals, Inc.  took a big hit when the company scuttled an important development program because of safety concerns.Investors Alert -Alnylam Pharmaceuticals, Inc.'s  - Hot Stocks PointAlnylam Pharmaceuticals, Inc.  Updated Broker Ratings - NewsDen"
p3
aS'Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It Motley Fool - Feb 9, 2017 The Medicines Company  presented more positive data for their cholesterol-lowering drug inclisiran, which was called ALN-PCSsc before Alnylam out-licensed the drug. The Medicines Company is running a new phase 2 trial in patients with&nbsp;...Alnylam Pharmaceuticals Inc.  Moves Higher on Volume Spike for February 09 - Equities.comAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial ... - Business Wire '
p4
aS'Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool - Feb 6, 2017 Agenus  and Alnylam Pharmaceuticals  are both clinical-stage biotechs developing drugs that hold the potential to make a big difference for patients.'
p5
aS'Alnylam Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 17 Equities.com - 17 hours ago Alnylam Pharmaceuticals Inc.  traded on unusually high volume on Mar. 17, as the stock gained 1.41% to close at $55.25.Alnylam Pharmaceuticals, Inc.  Upgraded by Vetr Inc. to Strong-Buy - Chaffey BreezeIs It Time to go for Alnylam Pharmaceuticals, Inc. , Envision Healthcare ... - StockNewsJournal'
p6
aS"What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure? Motley Fool - Oct 7, 2016 Alnylam Pharmaceuticals  announced on Oct. 5 that it was discontinuing development of revusiran in treating hereditary ATTR amyloidosis with cardiomyopathy .Alnylam Plunges 42% After Ending Development of a Key Medicine - BloombergAlnylam shares lose half their value as drug trial is halted - The Boston Globe"
p7
aS"Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data Motley Fool - Nov 4, 2016 Alnylam Pharmaceuticals  fell 12.6% on Thursday after reporting earnings Wednesday afternoon, but it's recovered some of that today."
p8
aS'Alnylam Pharmaceuticals Inc Risk Points versus Health Care CML News - Mar 15, 2017 This is a scatter plot analysis of the critical risk points from the option market for Alnylam Pharmaceuticals Inc  compared to its own past and the Health Care ETF.'
p9
aS'Investor Update on Shares of Alnylam Pharmaceuticals, Inc.  Davidson Register - 22 hours ago Investors may be tracking fundamental and technical data for Alnylam Pharmaceuticals, Inc. . The company has a current Value Composite Score of 90.Investor View: Looking at Shares of Alnylam Pharmaceuticals, Inc.  - Rives Journal'
p10
a.